The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
No sooner does one gammadelta-focused biotech die than another takes its place.
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The two companies have been involved in recent licensing deals.
